Therapeutic area

Renal and urinary disorders – page 32

580 clinical trials
226 recruiting
296 conditions
27 countries

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

580 clinical trials

Glomerulonephritis

Not recruiting

Study on the Safety and Effects of OMS906 for Patients with C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis

InvestigationalNo placebo

Study on the Safety and Effects of OMS906 for Patients with C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis

InvestigationalNo placebo

Lithuania

Participants:18–64 years · 65+ years
Substances:Oms906
Sponsor:Omeros Corp.

Contact Research Centre

Renal failure

Not recruiting

Study of RMC-035 to prevent kidney injury in patients undergoing open-chest heart surgery

Investigational

Study of RMC-035 to prevent kidney injury in patients undergoing open-chest heart surgery

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:Rmc-035
Sponsor:Guard Therapeutics International AB (publ)

Contact Research Centre

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Bay 3283142
Sponsor:Bayer AG

Contact Research Centre

Acute kidney injury

Not recruiting

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Tin816
Sponsor:Novartis Pharma AG

Contact Research Centre

Bladder cancer

Not recruiting

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

InvestigationalNo placebo

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cetrelimab
Sponsor:Grupo Espanol De Oncologia Genitourinaria-Socug

Contact Research Centre

B-cell lymphoma+8

Not recruiting

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

InvestigationalNo placebo

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cyc140 Monohydrochloride Monohydrate
Sponsor:Cyclacel Limited

Contact Research Centre

Study on Dapagliflozin and Balcinrenone for Patients Over 50 with Stage 3 Chronic Kidney Disease

Not recruiting

Registered drug

Study on Dapagliflozin and Balcinrenone for Patients Over 50 with Stage 3 Chronic Kidney Disease

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Balcinrenone
Sponsor:Klinikum Nuernberg

Contact Research Centre

A Study of Vildagliptin to Prevent Diabetes in Kidney Transplant Recipients During Early Post-Transplant Period

Not recruiting

Registered drugNo placebo

A Study of Vildagliptin to Prevent Diabetes in Kidney Transplant Recipients During Early Post-Transplant Period

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Vildagliptin
Sponsor:Centre Hospitalier Regional Universitaire

Contact Research Centre

Bladder cancer

Not recruiting

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Poloxamer 407
Sponsor:Urogen Pharma Ltd.

Contact Research Centre

Acute myeloid leukaemia+10

Not recruiting

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

InvestigationalNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Alport's syndrome

Not recruiting

Study on the Safety of Vonafexor for Patients with Alport Syndrome at Risk of Progression

InvestigationalNo placebo

Study on the Safety of Vonafexor for Patients with Alport Syndrome at Risk of Progression

InvestigationalNo placebo

France

Participants:18–64 years
Substances:Vonafexor
Sponsor:ENYO Pharma

Contact Research Centre

Clear cell renal cell carcinoma

Not recruiting

Study on the Effectiveness of Relatlimab, Ipilimumab, and Nivolumab in Patients with High-Risk Clear Cell Renal Cell Cancer

Registered drugNo placebo

Study on the Effectiveness of Relatlimab, Ipilimumab, and Nivolumab in Patients with High-Risk Clear Cell Renal Cell Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trials Nivolumab36 clinical trials Mycophenolate Mofetil24 clinical trials Dapagliflozin23 clinical trials Cabozantinib22 clinical trials Cisplatin22 clinical trials Ipilimumab21 clinical trials Gemcitabine20 clinical trials Sodium Chloride17 clinical trials

Renal and urinary disorders – page 32

Conditions in this area

Clinical trials in Renal and urinary disorders

580 clinical trials

Glomerulonephritis

Study on the Safety and Effects of OMS906 for Patients with C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis

Renal failure

Study of RMC-035 to prevent kidney injury in patients undergoing open-chest heart surgery

Diabetic retinopathy+1

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Acute kidney injury

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Bladder cancer

Study on Erdafitinib and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin Treatment

B-cell lymphoma+8

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

Study on Dapagliflozin and Balcinrenone for Patients Over 50 with Stage 3 Chronic Kidney Disease

Study on Dapagliflozin and Balcinrenone for Patients Over 50 with Stage 3 Chronic Kidney Disease

A Study of Vildagliptin to Prevent Diabetes in Kidney Transplant Recipients During Early Post-Transplant Period

A Study of Vildagliptin to Prevent Diabetes in Kidney Transplant Recipients During Early Post-Transplant Period

Bladder cancer

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

Acute myeloid leukaemia+10

Long-Term Access to Ibrutinib for Patients with Lymphoma, Leukemia, and Other Conditions

Alport's syndrome

Study on the Safety of Vonafexor for Patients with Alport Syndrome at Risk of Progression

Clear cell renal cell carcinoma

Study on the Effectiveness of Relatlimab, Ipilimumab, and Nivolumab in Patients with High-Risk Clear Cell Renal Cell Cancer

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.